After the coronavirus research race, vaccine producers face new hurdles
Reuters As more Covid-19 vaccines approach the finish line of regulatory approvals , the next challenge will be to produce and deliver hundreds of millions of doses as quickly as possible. Vaccines using traditional technology – like those developed in China – and the more advanced versions like Pfizer/BioNTech and Moderna’s mRNA vaccines – have very different hurdles to overcome. Experts said established technologies that used inactivated and vectored vaccines – like those being developed by China’s CanSino and Britain’s Oxford/AstraZeneca – had a short-term advantage because...